Baldwin Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.99M Buy
15,662
+108
+0.7% +$50.4K 0.82% 16
2025
Q4
$7.05M Sell
15,554
-194
-1% -$83.6K 0.8% 15
2025
Q3
$6.17M Buy
15,748
+1,207
+8% +$504K 0.71% 17
2025
Q2
$6.47M Buy
14,541
+711
+5% +$328K 0.78% 13
2025
Q1
$6.71M Buy
13,830
+1,271
+10% +$592K 0.81% 13
2024
Q4
$5.06M Buy
12,559
+668
+6% +$310K 0.66% 16
2024
Q3
$5.53M Buy
11,891
+135
+1% +$64.8K 0.69% 18
2024
Q2
$5.51M Buy
11,756
+1,407
+14% +$611K 0.75% 16
2024
Q1
$4.33M Buy
10,349
+976
+10% +$413K 0.59% 20
2023
Q4
$3.81M Buy
9,373
+347
+4% +$128K 0.6% 25
2023
Q3
$3.14M Buy
9,026
+533
+6% +$186K 0.52% 28
2023
Q2
$2.99M Buy
8,493
+130
+2% +$43.8K 0.49% 32
2023
Q1
$2.63M Buy
8,363
+52
+0.6% +$15.6K 0.47% 37
2022
Q4
$2.4M Buy
8,311
+535
+7% +$163K 0.43% 41
2022
Q3
$2.25K Buy
7,776
+259
+3% +$74.5K 0.46% 36
2022
Q2
$2.12K Sell
7,517
-99
-1% -$26.5K 0.4% 43
2022
Q1
$1.99K Buy
7,616
+917
+14% +$218K 0.3% 57
2021
Q4
$1.47K Buy
6,699
+649
+11% +$126K 0.23% 80
2021
Q3
$1.1M Sell
6,050
-55
-0.9% -$10.7K 0.19% 92
2021
Q2
$1.23M Buy
6,105
+240
+4% +$50.2K 0.21% 85
2021
Q1
$1.26M Buy
+5,865
New +$1.29M 0.23% 81

Other funds holding VRTX

Baldwin Investment Management's VRTX Position: Q1 2026 in Review

Baldwin Investment Management increased its Vertex Pharmaceuticals (VRTX) stake by 0.69% in Q1 2026, buying an estimated $50.4K and bringing the position to 15,662 shares worth $6.99M. The position accounts for 0.82% of the portfolio, ranked #16.

Baldwin Investment Management first reported a position in VRTX in Q1 2021 and has held it in 21 quarters since. The position peaked at $7.05M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Baldwin Investment Management held 15,662 shares of Vertex Pharmaceuticals worth $6.99M as of Q1 2026.
  • Baldwin Investment Management bought 108 Vertex Pharmaceuticals shares in Q1 2026, an estimated $50.4K.
  • Vertex Pharmaceuticals made up 0.82% of Baldwin Investment Management's portfolio in Q1 2026, its #16 holding.
  • Baldwin Investment Management first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 21 quarters since.
  • Baldwin Investment Management's Vertex Pharmaceuticals position peaked at $7.05M in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Baldwin Investment Management's 13F filing for Q1 2026, filed 12 May 2026.